What are the latest funding news in the longevity market? (July 2026)
Download our beautiful pitch about the longevity market
In our longevity market deck, you will find everything you need to understand the market
Longevity funding stayed active in the first half of 2026, but the latest public deals were concentrated before July.
The strongest rounds came from companies working on cellular reprogramming, rejuvenation therapies, preventive diagnostics, and regulated longevity drugs.
This list focuses only on companies where longevity, healthspan, biological aging, or age-related decline is central to the business.
And if you want to better understand this new industry, you can download our pitch covering the longevity market.
Insights
- Therapeutics dominated the period, with NewLimit, Life Biosciences, Loyal, Juvena, HexemBio, and Gero showing how longevity funding still leans heavily toward biotech
- The largest round was NewLimit’s $435.0M Series C, which alone represented more than half of the capital raised by the 12 companies in this list
- Preventive health platforms gained real traction, with Everlab and Lucis raising large Series A rounds by turning biomarker testing into longitudinal healthspan programs
- The market is not only about humans, as Loyal’s $100.0M canine longevity round shows that regulated animal health can be a serious longevity category
- Biological-age measurement moved closer to consumers, with Entourage AI raising pre-seed capital for aging clocks and organ-health tests based on blood samples
- Skin longevity became a fundable category, as Rapalogix positioned dermatology around cellular aging biology rather than generic beauty or skincare
- Australia appeared unusually visible in longevity clinics, with Everlab and TMRW both raising capital for preventive care and biomarker-led healthspan programs
- Valuations were rarely disclosed, but NewLimit’s $3.1B valuation and Everlab’s near $500M post-money valuation show investor appetite for scaled healthspan platforms
As this slide shows, and as featured in our longevity market deck, online search interest in longevity has been steadily increasing
Summary table of the latest funding deals in the longevity market as of July 2026
We define the longevity market as products and services that use science, medicine, or technology to extend healthy years of life and slow or improve the effects of aging.
We include therapies, diagnostics, clinics, digital tools, supplements, and programs that are explicitly designed and marketed to improve healthspan, prevent age-related decline, or optimize long-term health.
We exclude generic healthcare, wellness, beauty, fitness, eldercare, and financial products that serve older adults but are not specifically focused on longevity or healthspan.
You can also read our detailed analysis to understand how funding activity in the longevity market has evolved over the last few years.
We also have a quarter-by-quarter analysis of funding activity in the market here.
Finally, you can check our complete list of fundraising deals for the longevity market (we update this list every quarter) as well as our ranking of the most funded startups.
| Name | When | Amount in $ | Round Type | Category |
|---|---|---|---|---|
| Juvena Therapeutics | 12 January 2026 | $33.5M | Series B | Regenerative longevity therapeutics |
| L-Nutra | 21 January 2026 | $36.5M | Series D extension | Longevity nutrition & medical nutrition programs |
| Loyal | 11 February 2026 | $100.0M | Series C | Animal longevity therapeutics |
| TMRW | 9 March 2026 | $4.9M | Seed | Longevity clinic & membership platform |
| Entourage AI | 18 March 2026 | $5.0M | Pre-seed | Longevity diagnostics & biological-age testing |
| HexemBio | 6 to 7 April 2026 | $10.4M | Seed | Stem-cell rejuvenation therapeutics |
| Life Biosciences | 8 April 2026 | $80.0M | Series D | Epigenetic reprogramming therapeutics |
| Lucis | 26 May 2026 | $20.0M | Series A | Preventive health & biomarker platform |
| NewLimit | 3 June 2026 | $435.0M | Series C | Cellular reprogramming therapeutics |
| Everlab | 16 June 2026 | $46.0M | Series A | Preventive healthspan platform & longevity clinic model |
| Gero | 17 June 2026 | $17.0M | Equity financing | AI geroscience therapeutics |
| Rapalogix Health | 23 June 2026 | $20.0M | Series A | Longevity dermatology & therapeutic skincare |
All the latest funding deals during in the longevity market as of July 2026
Rapalogix Health raised $20.0M in Series A funding in June 2026
When was it?
The deal was announced on 23 June 2026.
Who are they?
Rapalogix Health develops cellular-longevity dermatology products, starting with Re-Q, a skin-health platform built around selective TORC1 biology.
Geographical focus?
Rapalogix Health is U.S. first, with professional dermatology and aesthetic practices as the initial commercial channel.
Why do we include them in the longevity market?
Rapalogix Health belongs in the longevity market because its core product is explicitly designed around skin longevity and cellular aging biology.
What is the company stage?
Rapalogix Health is in early commercial growth, with a launched professional skincare line and a pipeline of next-generation products.
How much did they raise?
Rapalogix Health raised $20.0M in this round.
What round is it?
The round was a Series A financing.
Why did they raise?
Rapalogix Health raised to expand Re-Q commercially, fund clinical research, and develop more products for skin longevity and age-related skin biology.
Gero raised $17.0M in new equity financing in June 2026
When was it?
The deal was announced on 17 June 2026.
Who are they?
Gero uses physics-first AI and longitudinal human health data to discover medicines that slow aging and treat age-related diseases.
Geographical focus?
Gero is headquartered in Singapore, has a U.S. subsidiary in San Francisco, and works with global pharma partners.
Why do we include them in the longevity market?
Gero belongs in the longevity market because its platform is built to model aging biology and discover drugs that slow aging.
What is the company stage?
Gero is a preclinical and platform-stage biotech with pharma collaborations.
How much did they raise?
Gero raised $17.0M in new financing, bringing total equity funding to $34.0M.
What round is it?
The financing was an equity round, and the round name was not disclosed.
Why did they raise?
Gero raised to advance preclinical aging-related drug programs and expand pharma partnerships built around its aging target-discovery engine.
This chart, featured in our longevity market deck, compares the main business model options for longevity clinics
Everlab raised $46.0M in Series A funding in June 2026
When was it?
The deal was announced on 16 June 2026.
Who are they?
Everlab offers an AI-enabled preventive healthcare platform combining diagnostics, doctors, prescriptions, wearables, and continuous care.
Geographical focus?
Everlab focuses on Australia and New Zealand today, with the UK as its first major international expansion market.
Why do we include them in the longevity market?
Everlab belongs in the longevity market because its platform is built to maximize healthspan through advanced diagnostics and preventive care.
What is the company stage?
Everlab is in growth stage, with 20,000 patients, more than 40,000 consultations, and corporate customers.
How much did they raise?
Everlab raised AU$65.0M, equivalent to about $46.0M.
What round is it?
The round was a Series A financing.
Why did they raise?
Everlab raised to strengthen clinical and technology infrastructure and roll out internationally, starting with the UK.
NewLimit raised $435.0M in Series C funding in June 2026
When was it?
The deal was reported on 3 June 2026 after the financing closed shortly before.
Who are they?
NewLimit develops epigenetic reprogramming medicines designed to restore youthful cell function, starting with liver programs.
Geographical focus?
NewLimit is a U.S.-based biotech with global therapeutic ambitions.
Why do we include them in the longevity market?
NewLimit belongs in the longevity market because its core technology directly targets cellular aging and rejuvenation.
What is the company stage?
NewLimit is preclinical and moving toward first human trials.
How much did they raise?
NewLimit raised $435.0M in this round.
What round is it?
The round was a Series C financing.
Why did they raise?
NewLimit raised after age-reversal results in old human liver cells, with plans to accelerate its first clinical asset into human testing.
This chart, featured in our longevity market deck, looks at Function Health’s strategy in longevity
Lucis raised $20.0M in Series A funding in May 2026
When was it?
The deal was announced on 26 May 2026.
Who are they?
Lucis turns blood biomarker testing and physician-reviewed AI insights into personalized preventive health recommendations.
Geographical focus?
Lucis is Europe-focused, with activity in France, the UK, Ireland, and Portugal, and expansion planned in Spain, Germany, and Italy.
Why do we include them in the longevity market?
Lucis belongs in the longevity market because it is built around biomarker-led prevention and long-term health optimization.
What is the company stage?
Lucis is in early growth, with more than 10,000 users and over one million biomarker tests delivered.
How much did they raise?
Lucis raised $20.0M in this round.
What round is it?
The round was a Series A financing.
Why did they raise?
Lucis raised to expand across Europe and keep building its AI health companion, longitudinal monitoring, personalization, and clinical safety.
Life Biosciences raised $80.0M in Series D funding in April 2026
When was it?
The deal was announced on 8 April 2026.
Who are they?
Life Biosciences develops cellular rejuvenation therapies using partial epigenetic reprogramming to reverse or prevent diseases of aging.
Geographical focus?
Life Biosciences is U.S.-based and initially focused on optic neuropathies.
Why do we include them in the longevity market?
Life Biosciences belongs in the longevity market because its platform is explicitly focused on cellular rejuvenation and diseases of aging.
What is the company stage?
Life Biosciences is a clinical-stage biotech entering Phase 1.
How much did they raise?
Life Biosciences raised $80.0M in this round.
What round is it?
The round was a Series D financing.
Why did they raise?
Life Biosciences raised to fund the Phase 1 trial of ER-100 and develop more candidates from its partial reprogramming platform.
In our longevity market deck, we identify pain points entrepreneurs should prioritize
HexemBio raised $10.4M in seed funding in April 2026
When was it?
The deal was announced on 6 to 7 April 2026.
Who are they?
HexemBio develops blood stem-cell rejuvenation therapies aimed at restoring aged hematopoietic stem-cell function.
Geographical focus?
HexemBio is a North America-focused biotech with global therapeutic potential.
Why do we include them in the longevity market?
HexemBio belongs in the longevity market because it targets the age-related decline of blood stem cells.
What is the company stage?
HexemBio is a seed-stage and preclinical biotech.
How much did they raise?
HexemBio raised $10.4M in this round.
What round is it?
The round was a seed financing.
Why did they raise?
HexemBio raised to advance IND-enabling studies and GMP manufacturing for its blood stem-cell rejuvenation platform.
Entourage AI raised $5.0M in pre-seed funding in March 2026
When was it?
The deal was announced on 18 March 2026.
Who are they?
Entourage AI is building protein-based aging clocks and organ-health tests from at-home blood samples.
Geographical focus?
Entourage AI is based in Scotland and has broader consumer-health potential.
Why do we include them in the longevity market?
Entourage AI belongs in the longevity market because its products measure biological age and organ aging.
What is the company stage?
Entourage AI is pre-seed stage, with preorders open and a research operations center launched.
How much did they raise?
Entourage AI raised $5.0M in this round.
What round is it?
The round was a pre-seed financing.
Why did they raise?
Entourage AI raised to launch the company, open the Glasgow research center, and bring its Aging Clock and Organ Health products toward market.
This market map, featured in our longevity market deck, highlights top companies and startups in the longevity market
TMRW raised about $4.9M in seed funding in March 2026
When was it?
The deal was reported on 9 March 2026.
Who are they?
TMRW runs a longevity membership platform combining biomarker testing, clinical guidance, and personalized healthspan programs.
Geographical focus?
TMRW is Australia-focused, especially around Sydney and Australian consumers.
Why do we include them in the longevity market?
TMRW belongs in the longevity market because its service is explicitly built around personalized longevity, biomarkers, and healthspan.
What is the company stage?
TMRW is seed-stage, with early commercial clinic and membership expansion.
How much did they raise?
TMRW raised about $4.9M, roughly AU$7.0M.
What round is it?
The round was a seed financing.
Why did they raise?
TMRW raised to expand personalized longevity programs and scale partnerships such as TruDiagnostic.
Loyal raised $100.0M in Series C funding in February 2026
When was it?
The deal was announced on 11 February 2026.
Who are they?
Loyal develops FDA-regulated drugs intended to extend healthy lifespan in dogs.
Geographical focus?
Loyal is U.S.-based and initially focused on the U.S. veterinary market.
Why do we include them in the longevity market?
Loyal belongs in the longevity market because its core product is a regulated longevity drug designed to extend healthy lifespan.
What is the company stage?
Loyal is a clinical-stage and near-market animal-health biotech.
How much did they raise?
Loyal raised $100.0M in this round.
What round is it?
The round was a Series C financing.
Why did they raise?
Loyal raised to advance LOY-002 toward FDA approval and move closer to market readiness for the first canine longevity drug.
This chart, featured in our longevity market deck, illustrates yearly funding for longevity startups
L-Nutra raised $36.5M in Series D extension funding in January 2026
When was it?
The deal was announced on 21 January 2026.
Who are they?
L-Nutra develops clinically tested nutrition programs for longevity, fasting-mimicking nutrition, and nutrition-as-medicine.
Geographical focus?
L-Nutra is U.S.-based with global expansion, and the new investment specifically supports MENA expansion through Abu Dhabi.
Why do we include them in the longevity market?
L-Nutra belongs in the longevity market because its core business is science-driven nutrition for longevity and healthspan.
What is the company stage?
L-Nutra is in growth stage, with clinical trials, patents, and commercial nutrition products.
How much did they raise?
L-Nutra raised $36.5M, bringing Series D proceeds to $83.5M.
What round is it?
The round was a Series D extension investment.
Why did they raise?
L-Nutra raised to create an Abu Dhabi joint venture and expand longevity and medical nutrition therapies globally.
Juvena Therapeutics raised $33.5M in Series B funding in January 2026
When was it?
The deal was announced on 12 January 2026.
Who are they?
Juvena Therapeutics develops AI-enabled regenerative biologics designed to restore tissue function in neuromuscular and age-related diseases.
Geographical focus?
Juvena Therapeutics is a U.S.-based clinical-stage biotech.
Why do we include them in the longevity market?
Juvena Therapeutics belongs in the longevity market because its regenerative biology platform targets tissue function in age-related disease.
What is the company stage?
Juvena Therapeutics is a clinical-stage biotech.
How much did they raise?
Juvena Therapeutics raised $33.5M in this round.
What round is it?
The round was a Series B financing.
Why did they raise?
Juvena Therapeutics raised to advance its regenerative biologics pipeline and support clinical-stage development.
Related blog posts
- How strong is fundraising in the longevity market right now?
- The most recent news in the longevity market
- How large is the longevity market in reality?
- The evolution of funding activity in the longevity market
- The main fundraising trends in the longevity market
- All the recent funding deals in the longevity market
- The startups that have raised the most funding in the longevity market
- The most highly valued startups in the longevity market
